Audio Seminars

Home | Contact Us | Newsletter | Usersclub | Books | Audio Seminars

Labcompliance On-line Audio Seminar

This seminar has been recorded and is available on CD and for instant download. All reference material as listed below and more is available on a special seminar website. The website is regularly updated with most recent information. In case there are questions related to the topic, they can be submitted through a web form and will be answered by the speaker. For ordering info click here
To share this seminar info with your colleagues, click here

On-line Audio Seminar 286

Implementing the New USP Chapter <1224> for Analytical Method Transfer

With SOPs, templates and examples for effective implementation

Recorded, available with all reference material at any time

Order Button

When validated methods are transferred between laboratories and sites, their validated state should be maintained to ensure the same reliable results in the receiving laboratory. So far there has not been an official guidance on what exactly is expected to maintain 'the validated state'. Now the USP has approved a new general chapter <1224> for official use in May 2012 with USP 35. Also the FDA has released an official guidance for analytical method transfer. Now it is a good time to learn how to conduct and document transfer of analytical procedures according to USP and FDA expectations. However, transferring analytical methods raises a number of questions.

Key Questions are:

  • Method transfer is easy, why should we go through a formal process?
  • Are there any specific FDA requirements?
  • Are there examples for FDA warning letters?
  • What are recommendations from USP?
  • The USP chapter suggests to base the extent of testing on risk. How to do this?
  • Should the receiving laboratory do full revalidation?
  • What should be tested in the receiving laboratory?
  • What are acceptance limits?
  • What are most common mistakes during method transfer?
  • Anything special to care about for transfer to other sites?
  • When are system suitability tests sufficient?
  • How much can I change a transferred method without revalidation?
  • I want to transfer our standard method to hi-speed HPLC. What to do?
  • When can 'official' method transfer be omitted, and when not?
  • What to do if acceptance criteria are not met? Should we follow a formal OOS?
  • What are the responsibilities of the transferring and receiving laboratories
  • How should we 'formally' document method transfer?

How does the this audio seminar help:

Answers will be presented by Dr. Ludwig Huber in a new interactive audio seminar. During the seminar, the speaker will present strategies and give practical recommendations. After the seminar, an extensive list of reference material like SOPs, templates and a checklist will help immediate and cost effective implementation.

During the interactive presentation you learn about:

  • FDA and International expectations for method transfer; USP, EU, ISPE, WHO
  • Examples of FDA warning letters and how to avoid them
  • The FDA Guidance on method transfer
  • The new USP chapter <1224>: history, status, contents
  • Four approaches for analytical method transfer and testing
  • How to select the best approach
  • Responsibilities of the transferring and receiving laboratory
  • Developing a transfer plan and a pre-approval protocol
  • Design and conduct of comparative studies
  • Criteria and approaches for risk based testing: what, when, how much?
  • The importance and selection of acceptance criteria
  • Dealing with technology transfer: validation requirements, regulatory notification.
  • Method transfer from standard HPLC to UHPLC
  • Most likely failures during method transfer and how to avoid them
  • Handling deviations from documented acceptance criteria
  • Criteria for transfer waiver (omission of formal transfer): when does it NOT work
  • Method transfer protocol and summary report

And for easy and instant implementation:
download 10+ documents from special seminar website

  • Slides as PowerPoint Presentation, Script, Questions and Answers
  • Master Plan template and examples: - Transfer of Analytical Methods and procedures
  • SOPs
    - Transfer of Analytical Methods
    - Validation of Chromatographic Methods
    - Change versus Adjustment of Analytical Methods
  • Case Study: Analytical Method Transfer Protocol
  • Checklist
    Transfer of Analytical Methods and Procedures
  • Reference Articles
    - Validation of Analytical Methods: Review and Strategy
    - Evaluation and Validation of Standard Methods
  • USP Stimuli Paper: Transfer of Analytical Procedures  (link)
  • 70 Page Primer: Validation of Analytical Methods
  • FDA Warning-letters and/or Inspectional observations related to method transfer
  • FDA Industry Guidance: Protocol for the Conduct of Method Transfer for Type C Medicated Feed Assay Methods
  • FDA Guidance and Policy:
    - Analytical Procedures and Methods Validation
  • ICH Guidelines for the Industry
    - Text
    and methodology for Validation of Analytical Procedures

Who should attend?

  • Everybody involved in method transfer
  • QA managers and personnel
  • Analysts and lab managers
  • Validation specialists
  • Training departments
  • Documentation department
  • Consultants

Date, time and duration

Recorded seminar, available at any time with all reference material

How to order

Pick one of the options in the table that fits your needs.

Recorded seminar - Web Download

  • Multiple persons - single site
  • Learn at your desk, meet in a seminar or conference room or share the audio file and reference material at your site.
  • Order includes all reference material.

US$ 399.-
Order Now Button

Recorded seminar - CD

  • Get the CD in your mail
  • Order includes all reference material.

US$ 399.-
Order Now Button

Special offer for Labcompliance Usersclub Members
Recorded Seminar- CD or Web download.

  • Order includes all reference material.
  • for Usersclub information and registration, click here

US$ 299.-
Order Now Button

Please forward to your colleagues

 just click here

About audio seminars

Online audio seminars are presented over the phone. During the live presentation attendees can:

  1. Study the printed slide material
  2. Watch the slides on a computer
  3. Watch the slides on a video screen in a seminar room
  4. Ask questions through email and web form

About Dr. Ludwig Huber

Dr. Ludwig Huber is the editor and author of Labcompliance. He has been conducting over 300 web and audio or video based seminars since 15 years and and he has given multiple presentations mainly on GLP/GMP, 21 CFR Part 11 and Validation around the world. This included seminars, workshops and presentations for the US FDA, SFDA, KFDA, HSA, ISPE, PDA, PIC/S and several national health agencies.

Dr. Ludwig Huber is a frequent presenter at IVT conferences and has been awarded as the 'Presenter of the Year' out of 170 speakers. This photo is from IVT's conference on Network Qualification with Ludwig Huber as plenary speaker.

Dr. Huber has published several books related to validation and compliance, for example: Validation of Computerized Analytical and Networked Systems. He was or still is a member of several committees, e.g., of the GAMP® Special interest group (SIG) on Laboratory Computers, PDA Part 11 task force, IVT task force on network infrastructure qualification and the European Compliance Academy. He frequently visited FDA in Rockville, VA, and participated in panel discussions with FDA professionals. For feedback from attendees of seminars and  for other information on Dr. Ludwig Huber, click here.

Dr. Ludwig Huber in Panel Discussions with FDA Officials

George Smith, FDA's national Part11 expert, at a panel discussion with Ludwig Huber during an IVT conference

Smith and Huber discussed and answered questions about computer system validation and e-records.
Ludwig Huber (right) and John Murray, FDA's Computer Validation Expert, (left), speaking at the IVT Computer System Validation Conference.
Mr. Murray explined FDA'snext steps for Part 11

Ludwig Huber (right) in a panel discussion with FDA inspectors and directors:
 Dr. Robert C. Horan, B Erik Henrikson,Joseph Famulare,  and Nicholas Buhay,